"The MDC has outstanding specialists in vascular medicine and single-cell analysis and is a driver for innovation. As a privileged partner, the MDC will play a decisive role in helping the BIH fulfill its mission of accelerating the translation of research findings from the lab to the clinic. That is good for patients in Germany and good for our research, so we are very pleased," said Thomas Sommer, interim Scientific Director of the MDC. The pursuit of translational, patient-oriented research and the application of our discoveries to improve human health are very close to our heart,” emphasizes Sommer.
‟It is especially positive that we can bring the vascular medicine expertise we have here in Berlin to bear in the BIH in an optimal way. The MDC is home to outstanding specialists who are studying diseases of the blood vessels, such as heart failure, heart attack, and stroke, and are already successfully collaborating with physicians at Charité, for example, on the. Now we can expand this collaboration,” says Sommer. The study aims to follow 10,000 patients who suffer from acute diseases of the blood vessels over many years in order to find out why some people survive the disease relatively well and why others don’t.
Cooperation is already a reality
The MDC has also attained internationally recognized excellence in single-cell analysis, a cutting-edge research approach that ultimately seeks to reliably predict disease onset and progression and to develop better treatment options. “In this field, the MDC already has strong ties to Charité, for example, when it comes to data sharing and analysis.” Here Sommer pointed out the. “We look forward to the intensive collaboration, whose aim is personalized medicine. We will be able to expedite scientific progress that benefits patients through the already excellent and fruitful collaboration of our researchers with Charité’s clinicians,” Sommer added.
Sommer stresses that the MDC is a driver of innovation and has state-of-the-art technologies and facilities, some of which have been jointly developed ‒ and are extensively used – by the MDC, Charité, and the BIH. This cooperation must continue, he says, highlighting the close proximity of the MDC to Germany’s largest university hospital.
Max Delbrück Center for Molecular Medicine in the Helmholtz Association (MDC)
Head of the Communications Department